The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.
Although many new molecular and genetic discoveries have been made in the ocular melanoma field in the past few years, much more research is needed to more fully understand how some of these discoveries will impact effective treatments for patients. In the a recent review article: http://www.hindawi.com/journals/pri/2011/159421/, some of the molecular differences between ocular and cutaneous melanoma are outlined.
Although many new molecular and genetic discoveries have been made in the ocular melanoma field in the past few years, much more research is needed to more fully understand how some of these discoveries will impact effective treatments for patients. In the a recent review article: http://www.hindawi.com/journals/pri/2011/159421/, some of the molecular differences between ocular and cutaneous melanoma are outlined. Although this article is largely up-to-date and accurate, it doesn't mention the GNA11 mutation in ocular melanoma. As many of you will know, the general numbers are that about 50% of ocular melanoma has a mutation in GNAQ and another 30% has a mutation in GNA11. From early research, it looks like the molecular signaling is similar between these two mutations, but research is ongoing to learn how to effectively target these mutations, and, if targeting these is enough to halt disease– current thinking is that the GNAQ and GNA11 mutations are part of the solution, but likely not the complete solution (for example, researchers are now looking into the role of the newly identified mutation in BAP1 and how this may interact to cause metastasis). As you can see from this article, research in ocular melanoma is behind research in cutaneous melanoma and some of the ongoing areas of ocular melanoma specific research are mentioned in the Conclusion section of this article.
Please feel free to post thoughts, questions, or experiences with some of these treatments (i.e. many ocular melanoma patients have had experiences with MEK-inhibitors and new trials are opening for IGF1-R inhibitors and other targeted therapies as well)…. please feel free to ask questions and share your experiences….
The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.
The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.